

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM727581

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Trademark Security Agreement (Term Loan)		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
AMNEAL PHARMACEUTICALS LLC		05/04/2018	Limited Liability Company: DELAWARE
Impax Laboratories, LLC		05/04/2018	Limited Liability Company: DELAWARE
Amedra Pharmaceuticals LLC		05/04/2018	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	JPMorgan Chase Bank, N.A., as administrative agent and collateral agent		
Street Address:	MC: NY1-C413, 4 Chase Metrotech Center		
City:	Brooklyn		
State/Country:	NEW YORK		
Postal Code:	11245		
Entity Type:	National Banking Association: UNITED STATES		
PROPERTY NUMBERS Total: 37			
Property Type	Number	Word Mark	
Registration Number:	3256227	AMNEAL	
Registration Number:	4163617	AMNEAL	
Registration Number:	4197066	AMNEAL PHARMACEUTICALS	
Registration Number:	4334315		
Registration Number:	5257430	FEMYNOR	
Registration Number:	4411523	GENERIC'S NEW GENERATION	
Registration Number:	5257427	LILLOW	
Registration Number:	4557571	LOMEDIA	
Registration Number:	4690032	LOPREEZA	
Registration Number:	5455072	MELODETTA	
Registration Number:	5312528	NORLYDA	
Registration Number:	0251253	PYRIDIDIUM	
Registration Number:	2341466	PYRIDIDIUM PLUS	
Registration Number:	2978031	REPREXAIN	
Registration Number:	5247584	THE WORLD IS OUR FAMILY	

CH \$940.00 3256227

Property Type	Number	Word Mark
Registration Number:	5257429	TRI FEMYNOR
Registration Number:	5101795	YUVAFEM
Registration Number:	4724116	RYTARY
Registration Number:	4782446	RYTARY
Registration Number:	4969799	IMPAX
Registration Number:	4961699	MYRYTARY
Registration Number:	4862811	NUMIENT
Registration Number:	4503141	LINEAGE THERAPEUTICS
Registration Number:	4503142	LINEAGE THERAPEUTICS
Registration Number:	4013212	AMEDRA
Registration Number:	1177791	DEXEDRINE
Registration Number:	5118599	E
Registration Number:	4969303	EMVERM
Serial Number:	87022187	EFYNORA
Serial Number:	87022190	ESTIFEM
Serial Number:	86379547	FOLVITE
Serial Number:	87761973	LOPRETTO
Serial Number:	87022198	TRI LO FEMYNOR
Serial Number:	87834517	ELURYNG
Serial Number:	87844912	WE MAKE HEALTHY POSSIBLE
Serial Number:	86511726	MYRYTARY
Registration Number:	3797506	ADRENACLICK

CORRESPONDENCE DATA

Fax Number: 2124552502

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2124552592

Email: jnull@stblaw.com

Correspondent Name: Courtney Welshimer

Address Line 1: 425 Lexington Avenue

Address Line 4: New York, NEW YORK 10017

ATTORNEY DOCKET NUMBER:	509265/2087
NAME OF SUBMITTER:	J. Jason Mull
SIGNATURE:	/J. Jason Mull/
DATE SIGNED:	05/12/2022

Total Attachments: 8

source=Project Apex - Term Loan Trademark Security Agreement [EXECUTED]#page1.tif

source=Project Apex - Term Loan Trademark Security Agreement [EXECUTED]#page2.tif

source=Project Apex - Term Loan Trademark Security Agreement [EXECUTED]#page3.tif

source=Project Apex - Term Loan Trademark Security Agreement [EXECUTED]#page4.tif

source=Project Apex - Term Loan Trademark Security Agreement [EXECUTED]#page5.tif

source=Project Apex - Term Loan Trademark Security Agreement [EXECUTED]#page6.tif

source=Project Apex - Term Loan Trademark Security Agreement [EXECUTED]#page7.tif

source=Project Apex - Term Loan Trademark Security Agreement [EXECUTED]#page8.tif

TRADEMARK SECURITY AGREEMENT

This TRADEMARK SECURITY AGREEMENT is dated as of May 4, 2018, by AMNEAL PHARMACEUTICALS LLC, a Delaware limited liability company, Impax Laboratories, LLC, a Delaware limited liability company, and Amedra Pharmaceuticals LLC, a Delaware limited liability company (each, individually, a “Grantor” and, collectively, the “Grantors”), in favor of JPMorgan Chase Bank, N.A., in its capacity as administrative agent and collateral agent (in such capacity, the “Collateral Agent”).

W I T N E S S E T H:

WHEREAS, the Grantors are party to that certain Term Loan Guarantee and Collateral Agreement dated as of May 4, 2018 (as amended, amended and restated, supplemented, refinanced, replaced, extended or otherwise modified from time to time, the “Security Agreement”) in favor of the Collateral Agent, pursuant to which the Grantors are required to execute and deliver this Trademark Security Agreement.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantors hereby agree with the Collateral Agent as follows:

SECTION 1. Defined Terms. Unless otherwise defined herein, terms defined in the Security Agreement and used herein have the meanings given to them in the Security Agreement.

SECTION 2. Grant of Security Interest in Trademark Collateral. As security for the payment or performance when due (whether at stated maturity, by acceleration or otherwise), as the case may be, in full of the Secured Obligations, each Grantor hereby pledges to the Collateral Agent, its successors and permitted assigns, for the ratable benefit of the Secured Parties, and hereby grants to the Collateral Agent, its successors and permitted assigns, for the ratable benefit of the Secured Parties, a security interest in all of such Grantor’s right, title, and interest in or to any and all of the following Intellectual Property now owned or at any time hereafter acquired by such Grantor or in which such Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the “Trademark Collateral”), including:

- (a) all Trademarks, including all registrations and applications therefore filed in the United States Patent and Trademark Office or any similar offices in any State of the United States (except for “intent-to-use” applications for trademark or service mark registrations filed pursuant to Section 1(b) of the Lanham Act, 15 U.S.C. § 1051, unless and until an Amendment to Allege Use or a Statement of Use under Sections 1(c) and 1(d) of the Lanham Act has been filed, to the extent that, and solely during the period for which, any assignment of an “intent-to-use” application prior to such filing would violate the Lanham Act), and all renewals thereof, including those listed on Schedule I;
- (b) all goodwill associated therewith or symbolized thereby;

- (c) all claims for, and rights to sue for, past or future infringements of any of the foregoing; and
- (d) all income, royalties, damages and payments now or hereafter due and payable with respect to any of the foregoing, including damages and payments for past or future infringement thereof.

SECTION 3. Security Agreement. The security interest granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interest granted to the Collateral Agent pursuant to the Security Agreement and the Grantors hereby acknowledge and affirm that the rights and remedies of the Collateral Agent with respect to the security interest in the Trademark Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event that any provision of this Trademark Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall control.

SECTION 4. Recordation. This Trademark Security Agreement has been executed and delivered by the Grantors for the purpose of recording the grant of security interest herein with the United States Patent and Trademark Office. Each Grantor authorizes and requests that the Commissioner of Trademarks record this Trademark Security Agreement.


SECTION 5. Counterparts. This Trademark Security Agreement may be executed in any number of counterparts, all of which shall constitute one and the same instrument, and any party hereto may execute this Trademark Security Agreement by signing and delivering one or more counterparts.

SECTION 6. Governing Law. THIS TRADEMARK SECURITY AGREEMENT AND ANY CLAIM, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER LOAN DOCUMENTS AND THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK (EXCEPT FOR CONFLICTS OF LAW PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION).

[Signature page follows]

IN WITNESS WHEREOF, each Grantor has caused this Trademark Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

AMNEAL PHARMACEUTICALS LLC,
as Grantor


By: 

Name: Chintu Patel

Title: President

[Signature Page to Term Loan Trademark Security Agreement]


IMPAX LABORATORIES, LLC,
as Grantor

By:  _____

Name: Bryan M. Reasons

Title: Senior Vice President and Chief Financial
Officer

AMEDRA PHARMACEUTICALS LLC,
as Grantor

By:  _____

Name: Bryan M. Reasons

Title: Chief Financial Officer

Accepted and Agreed:
JPMORGAN CHASE BANK, N.A.,
as Collateral Agent

By: 
Name: James A. Knight
Title: Executive Director

[Signature Page to Term Loan Trademark Security Agreement]


TRADEMARK
REEL: 007720 FRAME: 0393

SCHEDULE I
to
TRADEMARK SECURITY AGREEMENT

TRADEMARK REGISTRATIONS AND TRADEMARK APPLICATIONS

	Trademark/Image if any	Application Number Application Date	Registration Number Registration Date	Owner
1.	AMNEAL	78954969 18-AUG-2006	3256227 26-JUN-2007	AMNEAL PHARMACEUTI CALS LLC
2.	AMNEAL	85376933 21-JUL-2011	4163617 26-JUN-2012	AMNEAL PHARMACEUTI CALS LLC
3.		85377805 21-JUL-2011	4197066 28-AUG-2012	AMNEAL PHARMACEUTI CALS LLC
4.		85724888 10-SEP-2012	4334315 14-MAY-2013	AMNEAL PHARMACEUTI CALS LLC
5.	EFYNORA	87022187 02-MAY-2016	Allowed	AMNEAL PHARMACEUTI CALS LLC
6.	ESTIFEM	87022190 02-MAY-2016	Allowed	AMNEAL PHARMACEUTI CALS LLC
7.	FEMYNOR	87022202 02-MAY-2016	5257430 01-AUG-2017	AMNEAL PHARMACEUTI CALS LLC
8.	FOLVITE	86379547 28-AUG-2014	Allowed	AMNEAL PHARMACEUTI CALS LLC
9.	GENERIC'S NEW GENERATION	85376971 21-JUL-2011	4411523 01-OCT-2013	AMNEAL PHARMACEUTI CALS LLC
10.	LILLOW	87021857 02-MAY-2016	5257427 01- AUG-2017	AMNEAL PHARMACEUTI CALS LLC
11.	LOMEDIA	86082154 03-OCT-2013	4557571 24-JUN-2014	AMNEAL PHARMACEUTI CALS LLC
12.	LOPREEZA	86321948 26-JUN-2014	4690032 17-FEB-2015	AMNEAL PHARMACEUTI CALS LLC

13.	LOPRETTO	87761973 19-JAN-2018	Pending	AMNEAL PHARMACEUTI CALS LLC
14.	MELODETTA	87479387 07-JUN-2017	5455072 24-APR-2018	AMNEAL PHARMACEUTI CALS LLC
15.	NORLYDA	87021876 02-MAY-2016	5312528 17-OCT-2017	AMNEAL PHARMACEUTI CALS LLC
16.	PYRIDIUM	71272349 13-SEP-1928	0251253 01-JAN-1929	AMNEAL PHARMACEUTI CALS LLC
17.	PYRIDIUM PLUS	75749622 28-JUN-1999	2341466 11-APR-2000	AMNEAL PHARMACEUTI CALS LLC
18.	REPREXAIN	76584625 25-MAR-2004	2978031 26-JUL-2005	AMNEAL PHARMACEUTI CALS LLC
19.	THE WORLD IS OUR FAMILY	87065214 08-JUN-2016	5247584 18-JUL-2017	AMNEAL PHARMACEUTI CALS LLC
20.	TRI FEMYNOR	87022193 02-MAY-2016	5257429 01-AUG-2017	AMNEAL PHARMACEUTI CALS LLC
21.	TRI LO FEMYNOR	87022198 02-MAY-2016	Allowed	AMNEAL PHARMACEUTI CALS LLC
22.	YUVAFEM	86829218 23-NOV-2015	5101795	AMNEAL PHARMACEUTI CALS LLC
23.	ELURYNG	87834517 14-MAR-2018	Pending	AMNEAL PHARMACEUTI CALS LLC
24.	WE MAKE HEALTHY POSSIBLE	87844912 22-MAR-2018	Pending	AMNEAL PHARMACEUTI CALS LLC
25.	RYTARY	85586918 April 2, 2012	4724116 April 21, 2015	Impax Laboratories, LLC
26.	RYTARY & Design 	85931781 May 14, 2013	4782446 July 28, 2015	Impax Laboratories, LLC
27.	IMPAX & Design 	86517414 January 28, 2015	4969799 May 31, 2016	Impax Laboratories, LLC
28.	MYRYTARY	86978765 January 22, 2015	4961699 May 17, 2016	Impax Laboratories,

				LLC
29.	NUMIENT	86598890 April 15, 2015	4862811 December 1, 2015	Impax Laboratories, LLC
30.	MYRYTARY	86/511726 January 22, 2015	Allowed	Impax Laboratories, LLC
31.	Adrenaclik	77818149 September 2, 2009	US Reg. No. 3,797,506 June 1, 2010	Impax Laboratories, LLC
32.	Lineage Therapeutics	85890350 March 29, 2013	4503141 March 25, 2014	Impax Laboratories, LLC
33.	Lineage Therapeutics (& Design) 	85890354 March 29, 2013	4503142 March 25, 2014	Impax Laboratories, LLC
34.	Amedra	77932673 February 10, 2010	4013212 August 16, 2011	Amedra Pharmaceuticals LLC
35.	Dexedrine	73266838 June 18, 1980	1177791 November 17, 1981	Amedra Pharmaceuticals LLC
36.	E Design 	87046425 May 23, 2016	5118599 January 10, 2017	Amedra Pharmaceuticals LLC
37.	EMVERM	86274536 May 7, 2014	4969303 May 31, 2016	Amedra Pharmaceuticals LLC